How did RCEL's revenue and expenses trend in Q4 2024 compared to previous quarters?

**AVITA Medical (RCEL) experienced a significant increase in revenue in Q4 2024 compared to the previous quarter**, with total revenue reaching $64.25 million. This is a substantial rise from the $45.85 million reported in Q3 2024. However, there is no corresponding data on expenses for Q4 2024, which makes it difficult to analyze the trend in expenses for this period compared to previous quarters.

1. **Comparison of Revenue**:
- Q4 2024: $64.25 million
- Q3 2024: $45.85 million
- Q2 2024: $50.14 million
- Q1 2024: $11.1 million

|code|Ticker|Name|Date|Total Revenue (FY)|Total Revenue (FY) YoY|market_code|
|---|---|---|---|---|---|---|
|RCEL|RCEL.O|AVITA Medical|2023|5.0143E7|45.675605008570344|186|
|RCEL|RCEL.O|AVITA Medical|2024||28.135532377400637|186|

The data indicates that while revenue has shown a seasonal pattern with a significant spike in Q4 2024, there is no available data on expenses for this period. Therefore, a comprehensive analysis of the trend in expenses compared to previous quarters cannot be provided without additional information on Q4 2024 expenses.